The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Combining brentuximab vedotin and nivolumab in Hodgkin lymphoma: advice & clinical considerations
In this video, Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, comments on the promising results of combining brentuximab vedotin and nivolumab with other therapies, such as chemotherapy and radiation, in the treatment of Hodgkin lymphoma. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
